Novel Drug Designing and Developing Interventions by using Pharmaceutical Technologies

The drug design focuses on all fields of including drug discovery, drug design by rational approach, target-based design, drug synthesis, drug metabolism, structure-based drug design, molecular modeling, ligand-based interaction, development of the generic drug, in silico chemo informatics and bioinformatics technologies. Design for reliability in drug development, Design for traditional Chinese medicine clinical trials, Bayesian sequential design for multi-regional design, Design and analysis for target clinical trials, Design and analysis for diagnostic procedures, Adaptive design for early clinical development, Design for biosimilar studies, Design for bioassay development and validation, Design for statistical genetics, Design for assessment of drug to drug interaction, Design for bridging studies, Design for stability analysis, etc. From the fore-going, it is evident that laboratory-based clinical investigations remain pivotal in the successful hunting of any therapeutic intervention. However, these investigations are found to be resource-consuming, expensive and time-wasting. Since serendipity has eluded discovery and designing of therapies, clinical approaches are irrational, and computing knowledge as well as application of artificial intelligence have escalated, computer-assisted approaches and robotic devices have therefore crept into the processes of discovery, design and development of therapeutic interventions. The entire processes of hunting for therapies had transited into Computer-Aided Drug Design. This approach to innovating therapies spans from the computerassisted designing of drug molecules (Molecular Modeling) and Structure-based Modifications to the Absorption, Distribution, Metabolism and Excretion (ADME) assessment and, the largescale determination of the drug side effects that recently benefitted from the rationality of computation. Other therapeutic interventions that would not have come out of serendipity are the trans- Atlantic surgery and the machinemanaged insulin delivery device for the diabetics.

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial. Journal is now accepting manuscripts for its upcoming issue Volume 9 Issue 4 and also for special issue on Role of Hydroxychloroquine and chloroquine in treatment of COVID 19. Special Issue aims to publish manuscripts explaining drug synthesis, trails, production, action on viral molecules, chemical formulation, treatment reports etc. Authors may submit original research article, review article, case studies, short commentary, systemic reviews, editorials etc.

Mail us at drugdesign@eclinicalsci.org if interested and for queries.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org